A RAS inhibitor wins FDA approval in metastatic pancreatic cancer at $39,800 a month

Start with the arithmetic a pharmacy and therapeutics committee will run before it drafts a prior-authorization rule. The median overall survival difference in RASolute 302 was 6.5 months, 13.2 against 6.7 for standard-of-care chemotherapy in the intent-to-treat population ^[4][1]. At the disclosed wholesale acquisition cost of $39,800 a month ^[8], a patient who stayed on therapy through those 13.2 months accrues roughly $525,000 in list-price drug cost ^[3], which works out near $970,000 per life-year gained before any discount ^[4].

The thing that figure does not tell you is what a plan actually pays. WAC is a list price, and oncology rebates are neither public nor trivial. Medians are also not patients: nobody is treated for exactly 13.2 months, and the material here does not report time on treatment, the hazard ratio, or tolerability, each of which moves the real per-patient cost in either direction.

The commercial denominator came from the company's own analyst call. Revolution cited the Patient Metrics module of Oracle Life Sciences' CancerMPact for about 55,000 annual PDAC diagnoses, 74 percent of them (some 41,000) reaching first-line treatment, and 46 percent of those (some 19,000) reaching second line, the latter figure from a 2022 study the company cited ^[13]. That pool is soft at both edges. The label also covers adults who are not candidates for multiagent systemic therapy ^[2], which is not the same population as second line, and single-arm assumptions about uptake and duration do a lot of quiet work in any sales projection built on it.

The effect size earns its enthusiasm. Metastatic pancreatic cancer carries a five-year survival of 3 percent by American Cancer Society figures, against 13 percent across all stages ^[12], and a 1.97-fold increase in median survival ^[2] in a previously treated setting is not the usual Phase III outcome. Angelo de Claro, who directs FDA's Oncology Center of Excellence, called it "unprecedented results in an area of high unmet need" in the agency's approval statement ^[11]. The drug is described as a first-in-class RAS(ON) multi-selective and mutant-selective inhibitor ^[3].

What ran fast was the regulatory clock, not the payer clock. Approval arrived 6.5 months before the March 11, 2027 PDUFA date, after Breakthrough Therapy and Orphan Drug designations, a Priority Review, and acceptance into the Commissioner's National Priority Voucher pilot ^[9], whose target review window is one to two months instead of the standard ten to twelve ^[10]. Coverage determinations, appeals pathways and specialty pharmacy logistics do not compress on that schedule.

My read: the biology question for this line of therapy is answered about as well as one Phase III can answer it, and the variable that decides whether oncology programs can deliver the drug is net price per month of therapy, which nobody outside the negotiation knows. GEN reported investors as split on precisely that question ^[7], which is a defensible place to be sitting.